PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ERT Achieves Cardiac Safety Milestone After Completing 150th TET Trial - ERT, a leading provider of centralized ECG, ePRO and other services to the biopharmaceutical, medical device and related industries has celebrated a significant milestone by completing its 150th Thorough QT clinical trial (TET)
ERT Achieves Cardiac Safety Milestone After Completing 150th TET Trial

 

NewswireToday - /newswire/ - Philadelphia, PA, United States, 2009/09/04 - ERT, a leading provider of centralized ECG, ePRO and other services to the biopharmaceutical, medical device and related industries has celebrated a significant milestone by completing its 150th Thorough QT clinical trial (TET).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ERT provides full TET support to the biopharmaceutical industry, including consultation, study design and provision of ECG equipment to ECG analysis, data processing, management, reconciliation, reporting, quality control and regulatory support.

Cardiac safety concerns continue to be the primary reason for drugs being refused licenses or to carry restricted labeling and in the worst cases withdrawn from market completely. As a result, all new drugs are expected to undergo electrocardiographic testing (ECG) in the clinical development process and with the advent of the ICH E14 Guidance, a TET study is required for most drugs where more robust and rigorous ECG testing is performed. A TET study, unlike a typical Phase I clinical trial, costs in the region of $1.5 million to $2.5 million, highlighting the importance placed on these studies. It is estimated that a total of 300 TET studies have been carried out worldwide since the introduction of the guidance in 2005, which places ERT as the leader of TET expertise in the industry after completing its 150th study.

John Blakeley, Executive Vice President of ERT, said, “The TET study plays a crucial role in the development of a new pharmaceutical product. We are very excited to have supported the industry to help improve the cardiac safety of new drugs coming to market. We would like to take this opportunity to thank our partners and customers for placing their trust in us, and we look forward to continuing to build on this in the future. At ERT we only have one focus, which is the delivery of accurate and reliable results to our customers.”

ERT’s proven cardiac safety solutions offer a centralized process for the collection and analysis of quality ECG data. Its centralized core lab provides real-time collection of consistent, quality ECG data ― a critical element in the accurate assessment of a new drug’s cardiac effect. Centralization not only reduces inconsistencies that may occur from site to site, but also alleviates clients’ workloads. ERT simplifies ECG data management and analysis to provide on-demand, real-time access to ECG study data.

For further information on ERT and its technology and services please email info[.]ERT.com, call +1 215 972 0420.

About eResearchTechnology, Inc. (ERT)
Based in Philadelphia, PA, ERT (ert.com) is a leading provider of centralized ECG, ePRO, and other services to the biopharmaceutical, medical device, and related industries. ERT products and services are enabled by EXPERT®, the Company’s robust, secure, and validated clinical research workflow-processing system that powers centralized electronic data collection, data management, and information exchange.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


ERT Achieves Cardiac Safety Milestone After Completing 150th TET Trial

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Fiona Robinson 
+44 1477 539539 ert[.]scottpr.co.uk
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Inferior Vena Cava Filters Market to Register a Strong Growth by 2025 Notes Persistence Market Research
Plasma Component Separator Market Set to Surge Significantly During 2017-2025 Says PMR
Persistence Market Research Releases Fertility Enhancing Treatment Market Snapshot by 2017-2025
Disposable Diabetes Devices Market Expected to Generate Huge Profits by 2025 Finds Reports Persistence Market Research
Cardiac Biomarkers Market Expected to Generate Huge Profits by 2017-2025 Reports PMR
Stone Management System Market Foreseen to Grow Exponentially Over 2017-2025 Finds PMR
Global Hemoglobinopathy Market Worth US$ 788M by 2024 According to Persistence Market Research
Dentsu Announces its Corporate Venture Capital Fund Dentsu Ventures Investment in Grail
Xenex Receives Top Honors from Frost & Sullivan for LightStrike™ - the Only Pulsed Xenon UV Disinfection System in the Healthcare Market
Partners HealthCare and GE Healthcare Launch 10-year Collaboration to Integrate Artificial Intelligence into Every Aspect of the Patient Journey
US Acute Care Solutions Celebrates 2-Year Anniversary
GE Healthcare Receives FDA Indication Approval for Visipaque™ (iodixanol) Injection for use with Coronary CT Angiography
Telehealth Vendors Expand mHealth Portfolio to Conquer New Growth Opportunities Finds Frost & Sullivan
GE Healthcare Acquires Asymptote for Complete, Digitally-enabled Cryogenic Cold Chain Technology Supporting Safe Manufacture And Delivery Of Cellular
ANVISA Approval for EMCM Facilitates the Progress of Leader Biomedical Operations in Brazil

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Persistence Market Research (P) Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)